RedChip Investor Webinar with Jupiter Neurosciences (NASDAQ: JUNS)

Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage pharmaceutical company pioneering treatments for neuroinflammation and rare diseases through its proprietary resveratrol delivery platform. Its lead product, JOTROL™, offers groundbreaking bioavailability—nine times greater than traditional resveratrol formulations—enabling safe, effective treatment for CNS disorders like Alzheimer's and Parkinson's. Backed by elite research partnerships and a robust clinical pipeline, including multiple Phase 2 trials expected to launch within the next 12 months, Jupiter is also leveraging JOTROL to build a category-leading position in the high-growth Longevity & Healthspan market. Through a new direct-to-consumer business launching in Q3 2025, Jupiter will commercialize three JOTROL™-powered nutraceutical products designed to generate near-term revenue and position the company for profitability as early as 2026—supporting the advancement of its pharmaceutical trials in parallel.